Archived news

Launch of CPRD Aurum 

11 December 2017

CPRD is pleased to announce the launch of a new primary care database now available for public health research, known as CPRD Aurum. This will be offered as a distinct database from CPRD GOLD, with separate pricing.

The CPRD Aurum database contains routinely-collected data from primary care practices using the Egton Medical Information Systems electronic patient record system (EMIS-Web) software, different from the CPRD GOLD database which contains data contributed by practices using Vision software. Data content and health information contained in CPRD Aurum are similar to the CPRD GOLD database but are different with respect to structure and clinical coding.

Together, CPRD Aurum and CPRD GOLD offer customers greater flexibility when choosing the most suitable data to use for research. Our in-house researchers are happy to provide advice on which database to use depending on your research question.

CPRD Aurum will be implemented as a phased roll-out over the coming months, with the first database version released on Monday 11 December 2017. Further information about data release, how to access CPRD Aurum and the differences between CPRD GOLD and CPRD Aurum can be found via the CPRD Aurum page.

If you have any questions about CPRD Aurum please contact enquiries@cprd.com.


Help the MHRA to understand your needs and priorities

18 September 2017

The Medicines and Healthcare products Regulatory Agency is conducting a survey to better understand how it can support its customers

As part of the Medicines and Healthcare products Regulatory Agency’s continued commitment to deliver a high-quality service to its customers, stakeholders and partners, it is embarking on a major operational transformation programme across all three of its expert centres – the MHRA regulatory centre, the National Institute for Biological Standards and Control (NIBSC) and CPRD. This includes significant investment in the Agency’s digital capabilities and infrastructure.

Understanding your needs and priorities is essential to inform the Agency’s plans and will help it to strategically shape its services, investment decisions and underlying operational processes and systems. The work the Agency does now will underpin how it is able to meet your needs for years to come.

To help the Agency gain this insight, it has developed a short online survey – in collaboration with PA Consulting, a consulting, technology and innovation firm, and Woodnewton Associates, an independent strategic research agency – to help it understand more about your experience of working with the Agency and your views on where and how it needs to do things differently.

The survey should take about 10-15 minutes to complete, depending on how many different parts of the Agency you deal with. In line with the rules of the UK Market Research Society, your contribution will be held in strict confidence and information will not be passed to the Agency in a way that would allow any individual contribution to be identified. You can forward the survey on to others who you think would like to share their views with the Agency.

The survey closes on Wednesday 27th September 2017.

Complete the survey now 
 

Meet us at ICPE

15 August 2017

CPRD will be presenting a number of studies at this year’s International Conference for Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 28th-30th August 2017 in Montreal, Canada. If you are attending the event, please come along to find out how CPRD data is being used to answer important public health and clinical research questions.

Or you can visit us at stand 13. You will have the opportunity to meet representatives from our observational and interventional research teams and business development colleagues. CPRD supports real world academic, regulatory and industry clinical research worldwide through innovative use of UK health data for observational research and low burden clinical trial management.

Symposium 
Optimising design, conduct and interpretation of EHR-enabled randomised clinical trials: Case examples demonstrate the critical role of epidemiology and future challenges 
Date/Time: Wednesday 30 August, 10:30-12:00 
Room: 520CF 
CPRD-GSK-University of Manchester (Mark Wright and Rachael Williams)

Oral presentations 
Cardiovascular safety of vildagliptin: Pan-European non-interventional safety study 
Date/Time: Monday 28 August, 17:00-18:30 
Session: (Cardio) Vascular Safety Outcomes, 524AB 
Rachael Williams

Posters 
The use of acute hospital care by people with intellectual disabilities 
Date/Time: Monday 28 August, 08:00-18:00 
Session: Poster Session A: Health Care Utilisation & Costs, 220BC 
Jessie Oyinlola and Rachael Williams

Pancreatic cancer and vildagliptin: post-hoc analysis of the pan-European non-interventional safety study 
Date/Time: Monday 28 August, 08:00-18:00 
Session: Poster Session A: Pharmacovigilance – Cancer, 220BC 
Rachael Williams

Does pay-for-performance influence outcomes for people with serious mental illness? 
Date/Time: Tuesday 29 August, 08:00-18:00 
Session: Poster Session B: Informed Drug Policy, 220BC 
Rachael Williams

Pancreatic safety of vildagliptin: Pan-European non-interventional safety study 
Date/Time: Tuesday 29 August, 08:00-18:00 
Session: Poster Session B: Pharmacovigilance – Diabetes, 220BC

Find out more about ICPE in Montreal  
 

Our contact details have changed

2 May 2017

We have changed the name of our customer services system from CPRD Knowledge Centre to CPRD Enquiries.

This means that emails you receive will be from CPRD Enquiries and we will use our new email address enquiries@cprd.com

This change is part of our ongoing improvements to the efficiency of the CPRD point of contact system, and better reflects that we are here to respond to general enquiries as well as complex questions.

Any emails sent to our old email address will continue to reach us over the next few months. Our telephone number will remain the same and log in details for the customer website will not change.

CPRD contact details page 
 

Vacancies for Independent Scientific Advisory Committee Members

We are now seeking scientific members to join the MHRA Independent Scientific Advisory Committee (ISAC). We are interested in applicants with considerable expertise and research experience in select areas. 
 

Data Linkages

Following the announcement in July CPRD has now implemented the amendment to its policy on release of linked data. Linked data will only be released once ISAC has approved the study protocol. This policy will apply to any study in which patient level data are analysed, whether or not the results of the analysis will be published or otherwise communicated to third parties.

The following are excluded from this policy:

  • Incidence and prevalence counts, cohort definitions and simple counts of patient numbers for feasibility purposes
  • Linkage between primary care data and small area socio-economic status scores, solely in circumstance in which the results of analysis will not be published or otherwise communicated to third parties

Please note that for any studies which are to be published or otherwise communicated to third parties, prior ISAC approval of the study protocol is already required.

If you have any queries about this message, or would like any further information, please contact us at enquiries@cprd.com
 

Data Linkages – Clarification

CPRD is implementing an amendment to its policy on release of linked data. Once the revised policy is implemented, linked data will only be released once ISAC has approved the study protocol. This policy will apply to any study in which patient level data are analysed, whether or not the results of the analysis will be published or otherwise communicated to third parties.

The following will be excluded from this policy:

  • incidence and prevalence counts, cohort definitions and simple counts of patient numbers for feasibility purposes
  • linkage between primary care data and small area socio-economic status scores, solely in circumstance in which the results of analysis will not be published or otherwise communicated to third parties

The revised policy will be implemented from 1st September 2016. Please note that for any studies which are to be published or otherwise communicated to third parties, prior ISAC approval of the study protocol is already required.

If you have any queries about this message, or would like any further information, please contact us at enquiries@cprd.com 
 

Medicines and Healthcare products Regulatory Agency statement on the outcome of the EU referendum

27 June 2016

The Agency's response to the outcome of the EU referendum

Following the result of the referendum on the UK’s membership of the European Union, the focus of the Medicines and Healthcare products Regulatory Agency continues to be on our public health role. We will continue to work to the highest levels of excellence and quality, working with and supporting our customers, partners and stakeholders to protect health and improve lives.

Working closely with government we will consider the implications for the work of the Agency. We will continue to make a major contribution globally to improving public health through the effective regulation of medicines and medical devices, underpinned by science and research. 
 

Approved studies using CPRD Data

Applications to access CPRD data for observational research are reviewed the Independent Scientific Advisory Committee (ISAC). Approval by ISAC is required for researchers to carry out their proposed studies.

A summary of all ISAC approved protocols, including a lay and technical summary of the proposed research, are published 3 months after researchers have access to the data to begin their study.

Please click here to access the full list of the approved protocols. 

 

[Page last reviewed 27 April 2018]